Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic

Kučera, Radek; Topolčan, Ondřej; Pecen, Ladislav; Kinkorová, Judita; Svobodová, Šárka; Windrichova, Jindra; Fuchsova, Radka

doi:10.1016/j.cca.2015.02.036

Cited by 18 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levels of IGF-1 and IGFBP-3 are quite stable in circulation with a gradual fall with age after puberty and with different dynamics of the decline between females and males (11)(12)(13). Adjustment of IGF-1 and IGFBP-3 for age, as mentioned above, made it possible to perform more reliable interpretation of results.…”

Section: Discussionmentioning

confidence: 99%

“…The adjustment of serum levels at 60 years of age was performed to avoid the misleading results of IGF-1 an IGFBP-3 analyses. The age-specific reference values for serum IGF-1, IGFBP-3 and IGF-1/IGFBP-3 ratio was established in healthy Czech adults by using the linear regression model published by Kucera et al served as a guideline of the adjustment (11).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas

Kalfeřt

Ludvíková

Topolčan

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas

Kalfeřt

Ludvíková

Topolčan

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Nevertheless, CSRT appears to reduce this age-related effect on IGF-1/IGFBP-3 (a surrogate for IGF-1 bioavailability) between trained groups at rest, at the end of WAnT, and during recovery with important increases at all phases following the WAnT. IGF-1 bioavailability appears a strong predictor on the effectiveness of the IGF-1 action [ 92 ] and its increase confirms improvements of GH/IGF-1 axis in young and middle-aged trained men with training.…”

Section: Discussionmentioning

confidence: 99%

Combined sprint and resistance training abrogates age differences in somatotropic hormones

Sellami¹,

Dhahbi²,

Hayes³

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

The aim of this investigation was to compare serum growth hormone (GH), insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) in response to a combined sprint and resistance training (CSRT) program in young and middle-aged men.Thirty-eight healthy, moderately trained men participated in this study. Young and middle-aged men were randomly assigned to, a young training group (YT = 10, 21.4±1.2yrs) ora young control group (YC = 9, 21.6±1.8 yrs), a middle-aged training group (MAT = 10, 40.4±2.1 yrs) or a middle-aged control group (MAC = 9, 40.5±1.8 yrs). Participants performed the Wingate Anaerobic Test (WAnT) before and after a 13-week CSRT program (three sessions per week). Blood samples were collected at rest, after warm-up, immediately post-WAnT, and 10 min post-WAnT. CSRT induced increases in GH at rest and in response to the WAnT in YT and MAT (P<0.05). CSRT-induced increases were observed for IGF-1 and IGFBP-3 at rest in MAT only (P<0.05). Pre-training, GH, IGF-1 and IGFBP-3 were significantly higher at rest and in response to the WAnT in young participants as compared to their middle-aged counterparts (P<0.05). Post-training, YT and MAT had comparable basal GH (P>0.05). In response to the WAnT, amelioration of the age-effect was observed between YT and MAT for IGF-1 and IGF-1/IGFBP-3 ratio following CSRT (P>0.05). These data suggest that CSRT increases the activity of the GH/IGF-1 axis at rest and in response to the WAnT in young and middle-aged men. In addition, CSRT reduces the normal age-related decline of somatotropic hormones in middle-age men.

show abstract

“…The insulin-like growth factor 1 (IGF-1) and members of the IGF-binding protein family (IGFBPs) are essential for cell cycle regulation, with mitogenic and anti-apoptotic functions. However, these functions are tempered by binding to IGFBPs [67,68], as much of the circulating IGF-1 is bound to IGFBPs (mainly IGFBP-3). A very small percentage of IGF-1 remains in an unbound and biologically active form.…”

Section: Oncotarget 1221mentioning

confidence: 99%

“…The IGF-1 receptor (IGF-IR) has been implicated in PCa progression and progression to androgen-independent (AI) disease, as an androgens have been demonstrated to up-regulate insulin-like growth factor-I receptor (IGF-IR) expression and sensitize PCa cells to the biological effects of IGF-I. IGF-1 levels increase and IGFBP3 protein levels decrease during the progression of PCa [67][68][69][70]. We observed a reduction in serum IGF-1 in the isoflavone-treated group compared to placebo, although these reductions were not statistically significant.…”

Section: Oncotarget 1221mentioning

confidence: 99%

A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy

et al. 2020

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common cancer in American men. Additionally, African American Men (AAM) are 60% more likely to be diagnosed with PCa and 2.4 times more likely to die from this disease compared to Caucasian men (CM). To date, there are few strategies effective for chemoprevention for men with localized PCa. There is thus a need to continue to evaluate agents and strategies for chemoprevention of prostate cancer. Epidemiological, laboratory and early phase clinical trials have shown that the isoflavones modulates several biomarkers implicated in prostate carcinogenesis. The goal of this phase II randomized clinical trial was to explore the comparative effectiveness and safety of 40 mgs of aglycone isoflavones in AAM and CM with localized PCa in the pre-surgical period prior to radical prostatectomy. Thirty six participants (25 CM, 6AAM) were randomized to the isoflavone arm and 34 (25 CM, 7AAM) to the placebo arm, with 62 completing the intervention. Results indicated that isoflavones at a dose of 20 mgs BID for 3-6 weeks was well tolerated but did not reduce tissue markers of proliferation. A significant reduction in serum PSA was observed with isoflavone supplementation in CM compared to the placebo arm, but not observed in AAM. We observed no changes in serum steroid hormones with isoflavone supplementation. In AAM, a reduction in serum IGF-1 concentrations and IGF1: IGFBP-3 ratios were observed with isoflavone supplementation. Well-powered studies for longer duration of intervention may inform future trials with isoflavones, for chemoprevention of PCa.

show abstract

Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic

Cited by 18 publications

References 26 publications

Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas

Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas

Combined sprint and resistance training abrogates age differences in somatotropic hormones

A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy

Contact Info

Product

Resources

About